V
The startup develops a rose bengal photodynamic antimicrobial therapy that targets eye infections, specifically infectious keratitis, using a bioactive synthetic small molecule. This non-invasive approach provides an effective treatment option for ocular infections, enhancing patient outcomes and reducing the need for more invasive procedures.
Updated 3 months ago
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a rose bengal photodynamic antimicrobial therapy that targets eye infections, specifically infectious keratitis, using a bioactive synthetic small molecule. This non-invasive approach provides an effective treatment option for ocular infections, enhancing patient outcomes and reducing the need for more invasive procedures.